Follow-up study of non-A, non-B post-transfusion hepatitis

对4289例胃十二指肠良性疾病行胃大部切除术后输血后非甲非乙型肝炎的随访研究。他们的医疗记录进行了审查和个人识别信息，潜在的疾病，手术类型。获得手术日期、输血量、吸烟和饮酒习惯。使用Koseki系统定位生命状态，当患者死亡时，将死亡证明提交给法律的事务局。将观察到的死亡人数与预期人数进行比较，预期人数是通过将日本的日历、原因、性别和年龄特异性死亡率应用于风险人年计算得出的。在接受输血的患者中，肝细胞癌的死亡率升高，风险与输血量相关。从输血到肝癌死亡的潜伏期平均为21年。目前正在对丙型肝炎病毒携带者进行随访，以专门检查丙型肝炎病毒与肝硬化和肝细胞癌之间的关系。

Follow-up study of non-A, non-B post-tansfusion hepatitis among 4, 289 patients who had undergone partial gastrectomy for benign gastroduodenal diseases at university hospitals was carried out. Their medical records were reviewed and information on individual identification, underlying disease, type of operation. date of operation, volume of transfusion, and smoking and drinking habits was obtained. Vital status was located by using Koseki system and death certificates were referred to the Legal Affairs Bureau when patients were deceased. Observed number of deaths was compared with the expected number, which was calculated by applying person-years at risk with calendar-, cause-, sex- and age-specific mortality rates in Japan. Mortality from hepatocellular carcinoma among patients who received transfusion was elevated and the risk was correlated with the volume of transfusion. Latency period between transfusion and death from hepatocellular carcinoma was 21 years on average. Follow-up of hepatitis C virus carriers is now under way to specifically examine the association between hepatitis C virus and cirrhosis and hepatocellular carcinoma.